

# Multivisceral and Small Bowel Transplantation at Shiraz Organ Transplant Center

S. Nikeghbalian<sup>1\*</sup>, S. H. Mehdi<sup>1</sup>,  
M. Aliakbarian<sup>2,1</sup>, K. Kazemi<sup>1</sup>, A.  
Shamsaeefar<sup>1</sup>, A. Bahreini<sup>1</sup>,  
M. R. Mansoorian<sup>1</sup>,  
S. A. Malekhosseini<sup>1</sup>

<sup>1</sup>Shiraz Transplant Research Center, Shiraz  
University of Medical Sciences, Shiraz,  
Iran,

<sup>2</sup>Surgical Oncology Research Center, Imam  
Reza Hospital, Faculty of Medicine,  
Mashhad University of Medical Sciences,  
Mashhad, Iran

## ABSTRACT

**Background:** Multivisceral transplantations were initially done in animal models to understand the immunological effects. Later on, in human beings, it has been considered a salvage procedure for unresectable complex abdominal malignancies. With advancement in surgical techniques, availability of better immunosuppressive drugs, and development of better post-operative management protocols, outcomes have been improved after these complex surgical procedures.

**Objective:** To analyze and report results of multivisceral, modified multivisceral, and small bowel transplantations done at Shiraz Organ Transplant Center, Shiraz, southern Iran.

**Methods:** Medical records of all patients who underwent multivisceral, modified multivisceral, and small bowel transplants were retrospectively analyzed.

**Results:** There were 18 patients. The most common indications for the procedure in our series were unresectable carcinoma of pancreas followed by short bowel syndrome. 10 patients were alive after a median follow-up of 8.7 (range: 3–32) months. The remaining 8 patients died post-operatively, mostly from septicemia.

**Conclusion:** Multivisceral and small bowel transplantations are promising treatments for complex abdominal pathologies.

**KEYWORDS:** Multivisceral; Modified multivisceral; Small bowel; Transplantation; Animal model; Abdominal malignancies

## INTRODUCTION

The first multivisceral transplantation (MVTx) was done by Thomas Starzl, *et al*, more than 50 years ago in animal model to study the immunological effects with no intention for clinical application [1]. Lillehei, *et al*, also study the procedure in canine

model in the same era [2]. In mid-1980s, Starzl group performed the first human multivisceral transplantation, however, it was associated with marked surgical and immunological complications. Their first patients died shortly after transplantations [3].

Modern era of MVTx developed based on those pioneering works and became feasible when tacrolimus was introduced as an immunosuppressive agent in 1989. Various modifications were then introduced; in classical multivisceral transplantation, liver along with stomach, intestine and pancreaticoduo-

\*Correspondence: Mohsen Aliakbarian, MD, Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Nemazee Hospital, Zand Blvd, Shiraz, Iran  
Tel: +98-711-647-4308,  
Fax: +98-711-647-4307,  
E-mail: aliakbarianm@mums.ac.ir

denal complex (with or without spleen) are transplanted concurrently, while in modified multivisceral transplantation (MMVTx) the graft does not include liver [4]. Patients who are candidates for MVTx or MMVTx usually have no other surgical or medical treatment options [5]. Modified multivisceral and intestinal transplants are indicated in patients with intestinal failure before developing total parenteral nutrition (TPN)-associated liver failure. A liver biopsy is mandatory even if clinical and biochemical parameters show no signs of liver disease as only TPN-related cholestasis is reversible after intestinal transplantation [6, 7].

Recent advances in the surgical techniques as well as availability of more potent immunosuppressive drugs have led to improved survival. Although the incidence of PTLD have been increased as a side-effect of more immunosuppression, long-term outcome in some studies revealed that preservation of native spleen may prevent development of PTLD [8, 9].

We conducted this study to determine the outcome of all patients who received small bowel or MVTx at Shiraz Organ Transplant Center, Shiraz, southern Iran, between June 2010 and December 2012.

## MATERIAL AND METHODS

During the mentioned period, 18 patients underwent MVTx, MMVTx, and small bowel transplantation. Among them, eight had classical MVTx, four MMVTx, four isolated small bowel transplants, and two had combined pancreas and small bowel transplants.

Indications for performing the procedure can be categorized into three groups (Table 1):

Patients with benign processes which included short bowel syndrome, liver cirrhosis with extensive venous thrombosis and abdominal trauma (n=8). Moreover, in this group there was a case of pancreas transplant who developed chronic rejection of the transplanted pancreas and thrombosis in superior mesen-

teric vein for whom MMVTx (including small bowel and pancreaticoduodenal complex) was done.

Transplantation for low malignant potential tumors, which are usually slow-growing, including desmoid, neuroendocrine, and gastrointestinal tumors (n=5).

The last group included locally advanced malignancies that were not resectable with conventional techniques, including pancreatic carcinoma and hepatocellular carcinoma (n=5). There were some common characteristics in this group:

- All cases were young people.
- They had locally advanced tumors which were unresectable because of anatomical limitations like SMA involvement without any evidence of distant metastases.
- R0 resection was possible with *en-bloc* resection and MVTx.

One of the patients in this group underwent *ex vivo* resection of the pancreatic adenocarcinoma and small bowel autotransplantation and needed MVTx because of small bowel insufficiency three months after the first procedure. Another case underwent MVTx due to hilar involvement in a patient with hepatocellular carcinoma.

All donors were deceased and had a mean±SD age of 26±10.05 years. The most common cause of brain death was trauma (78%); all patients received ABO-identical grafts. Lymphocyte cross-match was done in all cases and transplants were done only in the presence of negative lymphocyte cross-match. Immunomodulation was not done pre-operatively for patients.

Harvesting was done as *en-bloc* procedure in all cases and any organ not needed in the procedure removed at back table dissection. Except in one case in whom split right lobe was used, whole liver grafts were used in classical MVTx.

All patients were induced with alemtuzumab

**Table 1:** Characteristics of recipients

Age	Sex	Pre-operative diagnosis	Tx	Treat Group*	Follow-up duration (month)	Present condition
30	M	Desmoid tumor	MVTx <sup>†</sup>	2	32	Alive
35	M	Hepatocellular carcinoma	MVTx	3	4	Exp
14	M	Neuroendocrine tumor	MVTx	2	4	Alive
35	F	Gastrointestinal stromal tumor	MMVTx <sup>‡</sup>	2	6	Exp
47	M	Small bowel insufficiency following ex-vivo resection of pancreatic carcinoma	MVTx	3	5	Exp
30	M	Carcinoma of the pancreas	MVTx	3	3	Alive
40	F	Chronic rejection of first pancreas transplant	MMVTx	1	2	Alive
50	M	Abdominal trauma	MMVTx	1	17	Alive
39	M	Carcinoma of the pancreas	MMVTx	3	4	Exp
50	F	Bowel gangrene	Small intestine	1	18	Exp
46	M	Abdominal trauma	Small intestine	1	13	Alive
55	F	Gastrointestinal stromal tumor	MMVTx	2	10	Exp
32	F	Neuroendocrine tumor	MVTx	2	10	Exp
43	M	Bowel gangrene	Small intestine	1	9	Alive
34	M	Bowel gangrene	Small intestine	1	7	Alive
51	M	Liver cirrhosis with extensive PV and SMV thrombosis	MVTx	1	6	Alive
26	M	Small round cell tumor	MVTx	3	3	Exp
29	F	Short bowel syndrome due to venous thrombosis	MMVTx	1	3	Alive

\*Treatment group: For this classification see the text

<sup>†</sup>Multivisceral transplantation<sup>‡</sup>Modified multivisceral transplantation

(Campath 1H). Maintenance immunosuppression included tacrolimus (trough level 12–15 ng/mL), mycophenolate mofetil 30 mg/kg/day and low dose steroids. Sirolimus was added in patients who developed renal dysfunction to reduce the dose of tacrolimus or to boost immunosuppression in patients with rejection episodes. Rejection episodes were treated with increasing dose of immunosuppressives, using high dose steroids or using biological agents, depending on the grade and severity of the episode.

All patients received prophylaxis against bacterial, fungal and viral infections. Episodes of infection were treated with appropriately according to culture and sensitivity reports.

Routine intestinal biopsies were taken through ileostomy stoma twice weekly for the first three weeks, followed by weekly for the next two months, and monthly afterward. In case of suspected rejection episode, biopsies were taken more frequently.

Intravenous feeding was started immediately in all patients after transplantation; it was followed by enteral feeding via jejunostomy tube. Enteral feeding was started with simple elemental formulae and slowly increased in both quantity and strength to full diet as tolerated by the patient.

### Recipient surgery

In classical MVTx, suprahepatic IVC was first anastomosed to the recipients' hepatic veins. The donor's abdominal aorta containing both celiac artery and superior mesenteric arteries were then anastomosed to the recipient infrarenal aorta in end-to-side fashion. In case of MMVTx, portal vein of graft was anastomosed to the portal vein of the recipient in end-to-end fashion.

Reconstruction of gastrointestinal system also depends on the type of transplantation. In case of classical MVTx and MMVTx, proximal anastomosis is performed between native esophagus and anterior wall of the stomach with pyloroplasty while distal end of the graft is exteriorized as end stoma after creating

side-to-side ileocolic anastomosis. In isolated intestinal transplantation, proximal anastomosis was made by duodenojejunostomy between recipient duodenum and graft jejunum. At the end, a jejunostomy tube was placed for enteral feeding.

## RESULTS

Between June 2010 and December 2012, we performed 18 MVTx and small bowel transplantation in our center. Out of these, eight underwent classical MVTx, four MMVTx, four isolated small bowel transplantation, and two had combined pancreas and small bowel transplantation. All patients were adults except one who was a 14-year-old male. The mean±SD age of patients was 38.1±10.6 years. Twelve patients were male and six were female. Indications for transplantation are shown in Table 1.

Total procedure took between 450 and 600 minutes. Total cold and warm ischemia time ranged from 130–720, and 30–90 minutes, respectively. The mean hospital stay was 41.4 (range: 22–64) days.

Complications following transplantations included major infection in five patients—one patient had large intra-abdominal collection, another had brain abscess, and three had severe sepsis. Other major complications were rejection episodes in seven patients, and GVHD in another patient. Recurrence of disease was not observed in our patients during the follow-up. Out of seven patients who experienced rejection episodes, one had mild grade 1 rejection and was treated with high dose steroids. In remaining six patients, the rejection was moderate to severe (grade 2 and 3) and was treated with ATG monoclonal antibody. One patient did not respond to any rejection treatments and died of severe rejection. GVHD was observed in only one patient in our series and managed by ATG monoclonal antibody.

Among the 18 patients, 10 were alive with a median follow-up of 8.7 (range: 3–32) months. Eight patients died during the follow-up.

Causes of death were severe sepsis in five patients; the remaining three died secondary to primary non-function of the liver, DVT and pulmonary emboli, and severe rejection.

## DISCUSSION

In the past 20 years, MVTx has evolved slowly and it is now considered a therapeutic option for patients with irreversible intestinal failure as well as unresectable complex abdominal pathologies [10-12]. The success rate of this procedure varies from center to center and depends on experience of the surgical team [13, 14].

There are several indications for MVTx and small bowel transplantation. After liver cirrhosis, portal vein thrombosis is the most common cause of portal hypertension. The major causes of non-cirrhotic portal hypertension include hypercoagulable states leading to spontaneous thrombosis, radiation, severe pancreatitis and intra-abdominal tumors [15]. In the presence of cirrhosis with portal vein thrombosis, liver transplantation can still be done in combination with thrombectomy or use of intervening jump graft. Nonetheless, in the presence of complete thrombosis of splanchnic circulation, the only viable option left is MVTx. Out of 18 patients we transplanted, one underwent MVTx for extensive splanchnic venous thrombosis.

Starzl, *et al*, did the first MVTx for unresectable abdominal malignancies. However, their results were very poor. On account of the recent advancements in technique and immunosuppression and use of strict selection criteria, the survival rate of patients undergoing MVTx becomes as high as 77% [16, 17]. Intra-abdominal malignancies constituted the most common indication for MVTx or small bowel transplantation in our series.

Trauma to abdomen is one of the known causes of severe combined solid organs and hollow visceral injuries that may result in chronic debilitating syndromes such as intestinal failure and pancreatic failure. TPN therapy is an op-

tion for survival in these patients but chronic TPN therapy can lead to life-threatening complications such as liver failure and line-related sepsis [18, 19]. MVTx or isolated small bowel transplantation is the treatment of choice for most of such patients.

The patients were transplanted because of different indications, but we divided the patients into three groups (Table 1): the indication for the first group who were transplanted for benign processes is internationally accepted. The second category included MVTx for surgical resection of slow-growing intra-abdominal tumors, is also accepted as the last choice for selected tumors otherwise unresectable in some centers. The last group is the most challenging indication. There is no general consensus among transplant community for the third group of our patients with locally advanced intra-abdominal malignancies and there is no consensus if visceral transplantation is an indication for this group of patients or not.

Nephrotoxicity is one of the most serious complications observed after transplantation. Renal damage is the result of pre-existing renal dysfunction in some of these patients as well as a side effect of calcineurin inhibitors. Biological agents such as ATG and alemtuzumab (Campath 1H) not only decrease the chance of developing nephrotoxicity but also have a proven role in long-term survival of both graft and the patient [11, 20, 21]. We used this strategy and all the patients received a biological agent as induction immunosuppression before transplantation in our series.

Post-transplant lymphoproliferative disorder (PTLD), which develops as a result of over-immunosuppression, is a common cause of late graft loss and mortality, especially after intestinal transplantation [22, 23]. Like PTLT, GVHD is also more common after intestinal transplantation than any other solid organ transplants, most likely due to the large number of donor cells in intestinal grafts. Unlike other series [10, 24], we observed only one case of GVHD and no one with PTLT and recurrence of disease, probably because of the

small number of patients in our series and short-term follow-up.

The overall survival in our series was 57% after a median follow-up of 8.7 months, which is not much different from other reports [10, 12]. All of the survivors have tolerated oral feeding and were not dependent on TPN therapy any more.

Eight patients in our series died after transplantation. The cause of death in five of them was septicemia. The main sources of sepsis were intra-abdominal including collections, anastomotic leakage and jejunostomy tube complications. There were different risk factors that predisposed the patients to major infections. Prolonged operative time (needed for tumor resection, retroperitoneal lymph node dissection and the implantation phase), excessive blood loss and transfusions, prolonged ischemic time of the grafts, potent immunomodulators like alemtuzumab and ATG with resultant leukopenia and inevitable multiple intestinal anastomoses in a patient with edematous and inflamed small intestine, were among the main reasons for serious infections in our series.

In conclusion, MVTx and small bowel transplant become acceptable treatment options for benign abdominal pathologies. However, we would not recommend it for intra-abdominal malignancies. Infection and septicemia are still major life-threatening complications in small bowel and MVTx.

## REFERENCES

1. Starzl TE, Kaupp HA, Jr. Mass homotransplantation of abdominal organs in dogs. *Surg Forum* 1960;**11**:28-30.
2. Lillehei RC, Goott B, Miller FA. Homografts of the small bowel. *Surg Forum* 1960;**10**:197-201.
3. Starzl TE, Rowe MI, Todo S, et al. Transplantation of multiple abdominal viscera. *JAMA* 1989;**261**:1449-57.
4. Starzl TE, Todo S, Tzakis A, et al. The many faces of multivisceral transplantation. *Surg Gynecol Obstet* 1991;**172**:335-44.
5. Mangus RS, Tector AJ, Kubal CA, et al. Multivisceral transplantation: expanding indications and improving outcomes. *J Gastrointest Surg* 2013;**17**:179-87.
6. Kato T, Ruiz P, Thompson JF, et al. Intestinal and multivisceral transplantation. *World J Surg* 2002;**26**:226-37.
7. Grosfeld JL, Rescorla FJ, West KW. Short bowel syndrome in infancy and childhood. Analysis of survival in 60 patients. *Am J Surg* 1986;**151**:41-6.
8. Abu-Elmagd K, Reyes J, Todo S, et al. Clinical intestinal transplantation: new perspectives and immunologic considerations. *J Am Coll Surg* 1998;**186**:512-25; Discussion 25-7.
9. Abu-Elmagd KM. Preservation of the native spleen, duodenum, and pancreas in patients with multivisceral transplantation: nomenclature, dispute of origin, and proof of premise. *Transplantation* 2007;**84**:1208-9; Author reply 9.
10. Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. *Ann Surg* 2009;**250**:567-81.
11. Grant D, Abu-Elmagd K, Reyes J, et al. 2003 report of the intestine transplant registry: a new era has dawned. *Ann Surg* 2005;**241**:607-13.
12. Tzakis AG, Kato T, Levi DM, et al. 100 multivisceral transplants at a single center. *Ann Surg* 2005;**242**:480-90; Discussion 91-3.
13. Vianna RM, Mangus RS, Tector AJ. Current status of small bowel and multivisceral transplantation. *Adv Surg* 2008;**42**:129-50.
14. Ruiz P, Kato T, Tzakis A. Current status of transplantation of the small intestine. *Transplantation* 2007;**83**:1-6.
15. Vianna RM, Mangus RS, Kubal C, et al. Multivisceral transplantation for diffuse portomesenteric thrombosis. *Ann Surg* 2012;**255**:1144-50.
16. Starzl TE, Todo S, Tzakis A, et al. Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. *Ann Surg* 1989;**210**:374-85; Discussion 85-6.
17. Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. *Liver Transpl* 2007;**13**:327-33.
18. Nishida S, Hadjis NS, Levi DM, et al. Intestinal and multivisceral transplantation after abdominal trauma. *J Trauma* 2004;**56**:323-7.
19. Kato T, Tzakis AG, Selvaggi G, et al. Intestinal and multivisceral transplantation in children. *Ann Surg* 2006;**243**:756-64; Discussion 64-6.
20. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. *Transplantation* 2003;**75**:1512-7.
21. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 2003;**349**:931-40.

22. Todo S, Reyes J, Furukawa H, *et al.* Outcome analysis of 71 clinical intestinal transplantations. *Ann Surg* 1995;**222**:270-80; Discussion 80-2.
23. Langnas AN, Shaw BW, Jr., Antonson DL, *et al.* Preliminary experience with intestinal transplantation in infants and children. *Pediatrics* 1996;**97**:443-8.
24. Cruz RJ, Jr., Costa G, Bond G, *et al.* Modified "liver-sparing" multivisceral transplant with preserved native spleen, pancreas, and duodenum: technique and long-term outcome. *J Gastrointest Surg* 2010;**14**:1709-21.